WOODCLIFF LAKE - Eisai Inc. presented the latest healthcare economic (HCEI) data for FYCOMPA (perampanel) CIII at the 2019 American Epilepsy Society Annual Meeting in Baltimore, Maryland.

Cumulatively, more than 35 scientific abstracts on FYCOMPA were presented by both Eisai and independent investigators, underscoring a collective and continued commitment to advancing research in epilepsy care.

In a retrospective study, researchers evaluated and compared use of all-cause and epilepsy-related healthcare services among patients, with an epilepsy diagnosis or non-febrile convulsions during the study period, treated with select AED combinations with and without FYCOMPA in a real-world clinical practice setting. The study followed patients 12 years who were treated with select AED treatment combinations, classified into three groups: FYCOMPA+ sodium channel blocker (SC), SC+SC and SC+ synaptic vesicle protein 2A binding (SV2). Outcomes were evaluated during a follow-up period of up to 12 months post-index treatment, and data was sourced from Symphony Health's Patient Integrated Dataverse database (08/2012-07/2018).

The real-world data analysis showed the rate of all-cause hospitalization to be significantly lower in the FYCOMPA+SC group vs both the SC+SC group (adjusted rate ratio [RR]=0.71; p

(C) 2019 Electronic News Publishing, source ENP Newswire